Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
On Friday, Johnson & Johnson's (NYSE: JNJ ) Zytiga received an expanded approval from the European Commission. The drug was previously approved for patients with metastatic castration-resistant prostate cancer who have failed a chemotherapy regimen that contains Sanofi's (NYSE: SNY ) Taxotere. The new approval expands the use of Zytiga into patients who have failed androgen deprivation therapy, but who aren't appropriate for chemotherapy yet.
The European Commission's decision is a rubber stamp on the European Medicines Agency's Committee for Medical Products for Human Use's decision in November to recommend the expanded marketing authorization.
The expanded approval is based on a clinical trial of more than 1,000 patients comparing Zytiga, plus prednisone/prednisolone, to placebo, plus prednisone/prednisolone. Patients in the Zytiga arm had a statistically-significant improvement in radiographic progression-free survival, a measure of how quickly a tumor begins to grow. Treatment with Zytiga also produced longer overall survival, although the trial was stopped early, so the difference didn't reach statistical significance.